Stocks & Indices Unverified First seen 2026-10-20 13:45 UTC

Arcus Biosciences reports Merck-rivaling kidney cancer data; shares dip then recover

Investor's Business Daily reported that Arcus Biosciences touted Merck-rivaling kidney cancer treatment results on Tuesday, while its shares initially fell sharply before recovering from steep losses. The post does not name the drug, give figures, or specify the size of the share move.

Why “Unverified”

Reported by Investor's Business Daily alone, with no second source or primary confirmation yet

1 independent source group across 1 post · evidence score 52/100. How labels work

What the sources claim

Arcus Biosciences touted kidney cancer treatment results that rival Merck's, according to Investor's Business Daily.

“Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday”
Investor's Business Daily
Arcus shares fell sharply before recovering from steep losses.

“shares took a swim”
Investor's Business Daily

Sources

Investor's Business Daily newswire 2026-10-20 13:45 UTC
Arcus Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer Data

More in Stocks & Indices

All Stocks & Indices stories →

Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-20 13:50 UTC. Labels are computed from the sources, not by the model.